Table 1.
Antiviral efficacy, measured by a reduction in CPE in virus-infected cells at Day 4 post-infection, and selectivity of astodrimer sodium against SARS-CoV-2 (hCoV-19/Australia/VIC01/2020) infection of Vero E6 cells.
| Compound/Assay Type | Repeat | EC50 (mg/mL) | CC50 (mg/mL) | SI |
|---|---|---|---|---|
| Astodrimer sodium added 1-h pre-infection | Assay 1 | 0.004 | 2.93 | 793 |
| Assay 2 | 0.012 | >0.863 | >70 | |
| Mean ± SD | 0.008 ± 0.006 | NC | >431a | |
| Astodrimer sodium added 1-h post-infection | Assay 1 | 0.002 | 3.29 | 2197 |
| Assay 2 | 0.011 | >0.863 | >80 | |
| Mean ± SD | 0.006 ± 0.007 | NC | >1138a | |
| Remdesivir added 1-h post-infection | Assay 1 | 0.59 μM | >20 μM | >33 |
| Assay 2 | 0.61 μM | >20 μM | >33 |
EC50 = 50% effective concentration; CC50 = 50% cytotoxic concentration; SI = selectivity index (CC50/EC50).
SD = standard deviation; NC = not calculated.
a
Average of Assay 1 and Assay 2 SI.